DRMAW — DERMATA THERAPEUTICS INC
As of Q2 2026, 1 SEC-registered investment managers reported holding DRMAW (DERMATA THERAPEUTICS INC) in their latest 13F filings, with a combined reported value of $18 across 1.80K shares. That is +38.3% by share count (+500 shares) versus the previous quarter, while reported value moved -10.0%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 1 added to existing stakes. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
| Fund | Quarter | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|---|
| UBS Group AG history | Q2 2026 | 1.80K | $18 | 0.00% | Add |
| Bank of America Corp history | Q4 2024 | 100 | $1 | 0.00% | Hold |
New Positions (Q2 2026)
No fund opened a new position this quarter.
Fully Exited (vs previous quarter)
No tracked fund fully exited this quarter.
Fund Position History — shares by quarter (top 2 funds)
| Fund | Q3 2021 | Q4 2021 | Q1 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UBS Group AG | 3.00K | 6.96K | 3.27K | 9.10K | 6.91K | 1.80K | 5.61K | 3.35K | 1.49K | 5.04K | 4.24K | 4.14K | 2.62K | 1.88K | 1.28K | 1.30K | 1.80K |
| Bank of America Corp | — | — | — | — | 100 | 100 | — | — | 100 | 200 | 100 | 100 | — | — | — | — | — |